News | June 10, 2022
Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
AbbVie receives the option to license worldwide rights to CUG252 from Cugene, a clinical-stage and potential best-in-class Treg-selective IL-2 mutein, building on AbbVie's commitment to developing novel therapies in immunology
The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone
Subscribe To Our Newsletter & Stay Updated
